Paul A Meyers MD

Pediatric Hematology & Oncology•New York, NY

Professor of Pediatrics, Cornell University-Weill Medical College

1275 York AvenueNew York, NY 10065

Dr. Meyers is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Meyers' full profile Already have an account?

Summary

Dr. Paul Meyers is a pediatric hematologist and oncologist based in New York, NY, with a distinguished career primarily associated with Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital since 1979. He specializes in pediatric sarcomas, including osteosarcoma, Ewing sarcoma, and other bone marrow failure syndromes. Dr. Meyers' academic background includes education from Brown University and the Icahn School of Medicine at Mount Sinai, with further training at Mt Sinai Hospital, Cornell Medical Center, and Sloan-Kettering Institute. He has been prolific in clinical research, authoring multiple publications and leading several clinical trials, focusing on innovative treatments for sarcoma and other pediatric cancers. His contributions to the medical field have been recognized through numerous accolades from Castle Connolly and the National Institutes of Health.

Education & Training

Memorial Hospital1978 - 1979
Sloan-Kettering Institute1977 - 1979
Cornell Medical Center1976 - 1976
Mt Sinai Hospital1974 - 1976
Mt Sinai Hospital1973 - 1974

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 1974 - 2028
NJ State Medical License 1982 - 2027
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2002-2014
America's Top Doctors Castle Connolly, 2002-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014

Clinical Trials

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
COMPLETED
PHASE2
Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma
COMPLETED
PHASE2
Trastuzumab in Treating Patients With Recurrent Osteosarcoma
COMPLETED
PHASE2

Publications & Presentations

PubMed

4 citations
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results.
Emily K Slotkin, Audrey Mauguen, Filemon S Dela Cruz, Michael V Ortiz, Viswatej Avutu
JCO Oncology Advances. 2025-01-01
11 citations
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.
Sujana Movva, Kenneth Seier, Viswatej Avutu, Lauren B Banks, Jason Chan
Clinical Cancer Research. 2024-12-16
20 citations
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.
Paul A Meyers, Noah Federman, Najat Daw, Peter M Anderson, Lara E Davis
Journal of Clinical Oncology. 2024-11-01

Journal Articles

Identification of lactoferrin as the granulocyte-derived inhibitor of colony-stimulating activity production.
Broxmeyer HE, Smithyman A, Eger RR, Meyers PA, de Sousa M, J Exp Med. 1978 Oct 1;148(4):1052-67
Inhibition of human erythropoietic colony formation in culture by treatment with Ia antisera.
Winchester RJ, Meyers PA, Broxmeyer HE, Wang CY, Moore MA, Kunkel HG, J Exp Med. 1978 Aug 1;148(2):613-8
Characteristics of bone marrow and blood cells in human leukemia that produce leukemia inhibitory activity (LIA).
Broxmeyer HE, Ralph P, Margolis V, Nakoinz I, Meyers PA, Kapoor N, and Moore MAS., Leukemia Research 1979; 3:193-203

Books/Book Chapters

Birth Defects Encyclopedia.
Chapter: Anemia, pernicious congenital
Meyers PAEditors: Buyse ML.Blackwell Scientific Publications, Cambridge MA
Current Treatment Options in Oncology.
Chapter: Ewing’s Sarcoma
Meyers PA, Levy AS
Therapy of Cancer in Children.
Chapter: Osteosarcoma and Ewing’s Sarcoma
Meyers PAEditors: Pratt C, Herzog C.Clinical Insights, New York

Lectures

The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

High dose therapy with autologous stem cell rescue for pediatric sarcomas.
Meyers PA, ASCO Education Book
Holcombe Grier Faculty of 1000 Medicine: evaluations for Meyers PA et al.
Paul A. Meyers, Cindy Schwartz, Mark Krailo, Eugenie Kleinerman, Donna Betcher, William Ferguson, Mark Gebhardt, Allen Goorin, Helen Nadel, Michael Nieder, Gene Sigel,..., J Clin Oncol 2008 Feb 1 26 (4) :633-8
http://www.f1000medicine.com/article/id/1100377/evaluation
Response to Osteosarcoma: Time to Move On?
Meyers PA, Kleinerman E, European Journal of Cancer
http://www.ecco-org.eu/News/News/EJC-Correspondence/Latest-Correspondence/Osteosarcoma-Time-to-move-

Press Mentions

$Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, Its First-in-Class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting$
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, Its First-in-Class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual MeetingNovember 14th, 2019
Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children’s Oncology Group MeetingNovember 5th, 2019
Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing SarcomaOctober 8th, 2019